Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)

Table 1 Schedule of data collection

	Baseline	Under treatment	At termination of treatment	After termination of treatment
Physical examination
Height	○
Weight, performance status	○	○	○
Blood pressure	○	○	○	○
Laboratory test
Blood count	○	○
Biochemistry test	○	○
Urine test	○	○
SpO₂	○	○		○^*1
Electrocardiography	○	○^*1
EGFR gene	○
Radiology test
Chest Xp	○	○^*1		○^*1
Chest CT	○	○^*2		○^*3
Abdominal CT/Ultra sonography	○	○^*2		○^*3
Head CT/MRI	○	○^*1		○^*1
Bone scintigraphy/PET	○	○^*1		○^*1

*1 If necessary
*2 Every 6 weeks
*3 Six weeks after termination if treatment is terminated for reasons other than progression of disease

ISSN: 1745-6215